Severe Bullous Drug Eruption and Filgrastim

Related Clinical Trial
Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis. Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren’s Syndrome, and Graft Vs Host Disease LYell SYndrome MEsenchymal Stromal Cells Treatment Severe Bullous Drug Eruption and Filgrastim Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation Severe Cutaneous Adverse Reactions in Thailand Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS) Stevens-Johnson Syndrome Antimicrobial Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye G-CSF in the Treatment of Toxic Epidermal Necrolysis Corneal Epitheliotropic Factors in Autologous Serum Eye Drops in Nonautoimmune and Stevens-Johnson Syndrome With Dry Eye Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study Topical Infliximab in Autoimmune Eyes With Keratoprosthesis HLA-B*5801 Screening to Prevent Allopurinol-induced Severe Cutaneous Adverse Reaction Drug Reactions Sampling (COLLECTIONTOXIDERMIES) Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN) Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis NATIENS: Optimal Management and Mechanisms of SJS/TEN

Brief Title

Severe Bullous Drug Eruption and Filgrastim

Official Title

Evaluating the Therapeutic Efficacy of Filgrastim in Severe Bullous Drug Eruptions (Lyell and Stevens-Johnson Syndromes)

Brief Summary

      Toxic epidermal necrolysis (TEN) including Stevens Johnson (SJS) and Lyell syndromes
      represent the most severe drug eruptions. It is an allergic disorder caused by cytotoxic T
      lymphocytes, specific of drugs, responsible for the destruction of keratinocytes by
      apoptosis. Regulatory T cell (CD25 high CD4+), normally responsible for controlling the
      activation of cytotoxic T lymphocytes, have altered function. Despite the progress made in
      the pathophysiological understanding of TEN, there is currently no effective treatment.

      The main symptom is bullous and skin peeling > 10% giving the appearance of great burns. The
      death rate is estimated between 30 and 40% due to visceral inflammatory injuries and
      bacterial superinfection. The risk of mortality is estimated during the initial treatment by
      calculating the SCORTEN (mortality>10% if SCORTEN>2, mortality>90% if SCORTEN>5). The
      morbidity is also very important (92% at 1 year), especially ophthalmologic with high risk of

      The therapeutic potential of G-CSF (Granulocyte-Colony Stimulating Factor) in TEN is
      supported by several observations.

      The G-CSF promotes skin healing. This has been shown in human burns, with a significant
      reduction in healing time under G-CSF. The mechanisms associate the growth factor effect on
      keratinocytes, macrophages stimulation and metalloprotease activity allowing tissue
      remodeling limiting sequels onset. Otherwise, healing altered in deficient G-CSF mice is
      corrected by the growth factor injection.

      The G-CSF is an immunomodulator whose activities appear to justify use in TEN :

        -  Polarization of immune response to Th2 non-cytotoxic (anti Th1),

        -  Preferential differentiation of naive LT (T lymphocytes) in regulator LT (CD25 high
           CD4+) and mobilization of regulator LT of the spinal cord to altered tissues.

      The G-CSF was used in a few cases of TEN with great efficacy. No data is available concerning
      sequels of SJS/TEN in treated patients.

      This clinical trial program, by providing proof of the efficacy of filgrastim in SJS/TEN,
      should allow progress in care of this serious toxics diseases. In the future, it could thus
      reduce the significant morbidity of these syndromes with a high rate of sequelae.

Study Phase

Phase 2/Phase 3

Study Type


Primary Outcome

Arrest of the SJS/NET progression at day 5

Secondary Outcome

 Arrest of the SJS/NET progression


Rare Diseases



Study Arms / Comparison Groups

Description:  Standard symptomatic treatment of the SJS/NET (until the reepidermization of the patient) + [email protected] (30 MU/0,5mL and/or 48 MU/0,5mL - solution of 20 ml diluted in GLUCOSE 5%) administrated by IV or subcutaneous route over a period of 5 consecutive days (1 injection per day during 30 minutes)


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

May 1, 2022

Completion Date

May 1, 2026

Primary Completion Date

May 5, 2025

Eligibility Criteria

        Inclusion Criteria:

          -  Patient aged of 6 years old or more, presenting SJS/TEN, drug or infectious origin
             proofed and very strongly suspected (indirect certainty argument), confirmed by

          -  SJS or TEN evolving since less than 7 days with a progression of the detachment or the
             eruption observed dating less than 48 hours.

          -  Patient and/or have right able to understand the objectives of the trial and having
             given their written consent to participate (parents for minors, have right for
             patients in immediate life-saving emergency).

          -  Patient registered with a social security scheme or benefiting from a similar scheme.

          -  Pregnancy test beta HCG negative for women of childbearing age

        Exclusion Criteria:

          -  Patient weighing less than 20kg

          -  Chronic myeloid pathology such as myeloid leukemia or AML (acute myeloid leukemia)

          -  Thrombophilia or thrombotic pathology in progress

          -  PNN (polymorphonuclear neutrophils) > 50.000 on the CBC (Complete Blood Count) during
             the inclusion visit

          -  Patient who received cyclosporine, anti-TNFalpha or intravenous immunoglobulins or
             lithium in the month prior the inclusion

          -  Pregnant or breastfeeding woman

          -  Patient under protective measure (safeguard measure, curatorship, guardianship) or
             deprived of liberty

          -  Patient in exclusion period after participation at other interventional clinical trial

          -  Known hypersensitivity to the active substance (FILGRASTIM) or to the one of the
             excipients (glutamine acid, sorbitol E420, Polysorbate 80)

          -  Patient presenting a known glucose intolerance or hereditary fructose intolerance

          -  Patient with a traumatic brain injury less than 24 hours

          -  Patient admitted with septic shock




6 Years - N/A

Accepts Healthy Volunteers



, 472 117 211, [email protected]

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party


Study Sponsor

Hospices Civils de Lyon

Study Sponsor

, , 

Verification Date

March 2022